BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16628682)

  • 1. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis.
    Dan YY; Wai CT; Yeoh KG; Lim SG
    Liver Transpl; 2006 May; 12(5):736-46. PubMed ID: 16628682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Goulis J; Akriviadis E; Papatheodoridis GV
    Liver Transpl; 2011 Oct; 17(10):1176-90. PubMed ID: 21656655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S; Ham MY; Stone MA; Holt C; Tong M
    Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
    Patterson SJ; Angus PW
    Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
    Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
    Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
    Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
    Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
    Wu B; Shen J; Cheng H
    BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
    Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
    Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation.
    Katz LH; Tur-Kaspa R; Guy DG; Paul M
    Cochrane Database Syst Rev; 2010 Jul; (7):CD006005. PubMed ID: 20614442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.